A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT ID: NCT05929066
Last Updated: 2025-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
2300 participants
INTERVENTIONAL
2023-07-10
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retatrutide Dose 1
Participants will receive retatrutide subcutaneously (SC).
Retatrutide
Administered SC
Retatrutide Dose 2
Participants will receive retatrutide SC.
Retatrutide
Administered SC
Retatrutide Dose 3
Participants will receive retatrutide SC.
Retatrutide
Administered SC
Placebo
Participants will receive placebo.
Placebo
Administered SC
Retatrutide Extension Period
Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks.
Retatrutide
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Retatrutide
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hypertension
* dyslipidemia
* obstructive sleep apnea, or
* cardiovascular disease
* History of of at least one unsuccessful dietary effort to reduce body weight
* Have index knee pain for \>12 weeks prior to screening, and presence of index knee pain for \>15 days over the previous month
* Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening
* Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA.
* Previously diagnosed with OSA
* Have AHI ≥15 on polysomnography at screening (definition of moderate-to-severe OSA)
* For participants not on positive airway pressure (PAP) therapy: unable or unwilling to use PAP therapy and have not used PAP for at least 4 weeks prior to screening.
* If on PAP therapy, have been on PAP therapy for at least 3 consecutive months prior to screening, and willing to temporarily stop using PAP therapy for approximately 7 days prior to each of the sleep study (PSG) visits.
* Have completed the final treatment visit of GZBJ Week 80.
Exclusion Criteria
* Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
* Have a prior or planned surgical treatment for obesity.
* Have diabetes mellitus.
* Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* Have had pancreatitis.
* Have had steroid joint injections within 90 days of screening.
* Have had other joint injections and procedures within 6 months of screening.
* Have joint disease other than osteoarthritis.
* Use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant, amphetamine) less than 3 months prior to screening.
* Use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months prior to screening.
* Use a dental appliance or other device to treat OSA other than PAP therapy.
* Have had study intervention discontinuation.
* Have had permanent dose reduction.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Phoenix Medical Clinic
Phoenix, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
Medical Investigations
Little Rock, Arkansas, United States
Neuro-Pain Medical Center
Fresno, California, United States
Valley Research
Fresno, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Teradan Clinical Trials, LLC
Brandon, Florida, United States
Suncoast Research Group
Miami, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Clinical Neuroscience Solutions
Orlando, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
NeuroTrials Research Inc
Atlanta, Georgia, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Northwestern University
Chicago, Illinois, United States
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
Springfield, Illinois, United States
Brengle Family Medicine
Indianapolis, Indiana, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States
MedVadis Research Corporation
Waltham, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Clinvest Research LLC
Springfield, Missouri, United States
Palm Research Center Tenaya
Las Vegas, Nevada, United States
Rochester Clinical Research, LLC
Rochester, New York, United States
Carteret Medical Group
Morehead City, North Carolina, United States
Trial Management Associates - Wilmington - Floral Parkway
Wilmington, North Carolina, United States
Lillestol Research
Fargo, North Dakota, United States
Altoona Center For Clinical Research
Duncansville, Pennsylvania, United States
Tribe Clinical Research, LLC
Greenville, South Carolina, United States
Tribe Clinical Research - Spartanburg
Spartanburg, South Carolina, United States
Vanderbilt Health One Hundred Oaks
Nashville, Tennessee, United States
FutureSearch Trials of Neurology
Austin, Texas, United States
Juno Research
Houston, Texas, United States
Advanced Research Institute
Ogden, Utah, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Rainier Clinical Research Center
Renton, Washington, United States
Emeritus Research
Botany, New South Wales, Australia
The AIM Centre / Hunter Diabetes Centre
Merewether, New South Wales, Australia
Logan Hospital
Meadowbrook, Queensland, Australia
Fusion Clinical Research
Adelaide, South Australia, Australia
Nightingale Research
Adelaide, South Aust, Australia
Emeritus Research
Camberwell, Victoria, Australia
Barwon Health
Geelong, Victoria, Australia
One Clinical Research
Nedlands, Western Australia, Australia
CPCLIN
São Paulo, São Paulo, Brazil
CPQuali Pesquisa Clínica
São Paulo, , Brazil
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, , Brazil
Aggarwal and Associates Limited
Brampton, Ontario, Canada
Dr. Steven V. Zizzo Medicine Professional Corporation
Hamilton, Ontario, Canada
Wharton Medical Clinic
Hamilton, Ontario, Canada
Your Research Network
Niagara Falls, Ontario, Canada
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, Canada
Canadian Phase Onward
Toronto, Ontario, Canada
Centre de Recherche Clinique de Laval
Laval, Quebec, Canada
Clinique de médecine Urbaine du Quartier Latin
Montreal, Quebec, Canada
C.I.C. Mauricie inc.
Trois-Rivières, Quebec, Canada
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, Csongrád megye, Hungary
Regia Med Kft
Székesfehérvár, Fejér, Hungary
Medifarma 98 Kft
Nyíregyháza, Nyíregyháza, Hungary
DRC Gyógyszervizsgáló Központ
Balatonfüred, Veszprém megye, Hungary
Óbudai Egészségügyi Centrum
Budapest, , Hungary
ClinDiab Kft.
Budapest, , Hungary
Debreceni Egyetem Klinikai Központ
Debrecen, , Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, , Hungary
Endolife Speciality Hospitals
Guntur, Andhra Pradesh, India
Avron Hospitals
Ahmedabad, Gujarat, India
Surat Institute of Digestive Sciences Hospitals
Surat, Gujarat, India
Karnataka Institute of Medical Sciences
Hubli, Karnataka, India
Indian Institute of Diabetes
Thiruvananthapuram, Kerala, India
Jothydev's Diabetes and Research Center
Trivandrum, Kerala, India
Wockhardt Hospital - Mumbai Central
Mumbai, Maharashtra, India
Deenanath Mangeshkar Hospital & Research Centre
Pune, Maharashtra, India
Chellaram Diabetes Institute
Pune, Maharashtra, India
Lifepoint Multispeciality Hospital
Pune, Maharashtra, India
All India Institute of Medical Sciences
Bhubaneswar, Odisha, India
Eternal Heart Care Center and Research Institute
Jaipur, Rajasthan, India
Christian Medical College Vellore
Vellore, Tamil Nadu, India
ILS Hospitals
Kolkata, West Benga, India
Centro de Investigacion en Artritis y Osteoporosis SC
Mexicali, Estado de Baja California, Mexico
Diseno y Planeacion en Investigacion Medica
Guadalajara, Jalisco, Mexico
Clinica de Investigacion en Reumatologia y Obesidad S. C.
Guadalajara, Jalisco, Mexico
Private Practice - Dr. Arechavaleta Granell Maria del Rosario
Guadalajara, Jalisco, Mexico
Unidad de Investigación Clínica y Atención Médica HEPA
Guadalajara, Jalisco, Mexico
RM Pharma Specialists
Mexico City, Mexico City, Mexico
Clinica Omega
Mexico City, Mexico City, Mexico
Instituto de Diabetes, Obesidad y Nutricion
Cuernavaca, Morelos, Mexico
Unidad biomedica avanzada monterrey
Monterrey, Nuevo León, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
EME RED Hospitalaria
Mérida, Yucatán, Mexico
Kohler and Milstein Research S.A. de C.V.
Mérida, Yucatán, Mexico
Centro de Atención e Investigación Clínica
Aguascalientes, , Mexico
Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos
Chihuahua City, , Mexico
Arké SMO S.A de C.V
Veracruz, , Mexico
Centrum Zdrowia Metabolicznego Pawel Bogdanski
Poznan, Greater Poland Voivodeship, Poland
INTERCOR
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Private Practice - Dr. Robert Witek
Tarnów, Lesser Poland Voivodeship, Poland
CenterMed Lublin NZOZ
Lublin, Lublin Voivodeship, Poland
Gabinety TERPA
Lublin, Lublin Voivodeship, Poland
MICS Centrum Medyczne Warszawa
Warsaw, Masovian Voivodeship, Poland
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, Podlaskie Voivodeship, Poland
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Pomeranian Voivodeship, Poland
NZOZ Salvia CM
Katowice, Silesian Voivodeship, Poland
Ambulatorium Sp. z o.o.
Elblag, Warmian-Masurian Voivodeship, Poland
Centrum Kliniczno-Badawcze
Elblag, Warmian-Masurian Voivodeship, Poland
Specjalistyczna Praktyka Lekarska Diabetologia, Leczenie Cukrzycy i Otylosci
Kielce, Świętokrzyskie Voivodeship, Poland
Ponce Medical School Foundation Inc.
Ponce, , Puerto Rico
Diabdana
Oradea, Bihor County, Romania
C.M.D.T.A. Neomed
Brasov, Brașov County, Romania
Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului
Bucharest, București, Romania
Gama Diamed
Mangalia, Constanța County, Romania
Cabinet Medical Dr.Geru
Timișoara, Timiș County, Romania
SC Minimed SRL
Bacau, , Romania
Diamed Obesity
Galați, , Romania
Centrul Medical Consultmed
Iași, , Romania
Clinica Korall
Satu Mare, , Romania
Policlinica Astra Sibiu
Sibiu, , Romania
CHUAC-Complejo Hospitalario Universitario A Coruña
A Coruña, A Coruña [La Coruña], Spain
Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval
Ferrol, A Coruña [La Coruña], Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital General Universitario de Valencia
Valencia, Valenciana, Comunitat, Spain
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, , Spain
Rowden Surgery
Chippenham, England, United Kingdom
Layton Medical Centre
Blackpool, Lancashire, United Kingdom
Leicester General Hospital
Leicester, Leicestershire, United Kingdom
Panthera Biopartners - North London
Enfield, London, City of, United Kingdom
Glasgow Royal Infirmary
Glasgow, Scotland, United Kingdom
Heartlands Hospital
Birmingham, , United Kingdom
Aintree University Hospital NHS Foundation Trust
Liverpool, , United Kingdom
St Clare Medical Centre
Penzance, , United Kingdom
Panthera Biopartners - Sheffield
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J1I-MC-GZBJ
Identifier Type: OTHER
Identifier Source: secondary_id
J1I-MC-GOA1
Identifier Type: OTHER
Identifier Source: secondary_id
J1I-MC-GSA1
Identifier Type: OTHER
Identifier Source: secondary_id
2023-503657-35-00
Identifier Type: OTHER
Identifier Source: secondary_id
18557
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.